X4 Pharmaceuticals, Inc
- Last sale
- Nov 12, 2026 · -1.40%
- Market cap
- $324.21M
- 102.11M shares
- Filings
- 821
Q3 2026+1,273.2% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+289.7% FY25 yoy
- $324.21M
- —
- 19.1×
- 2.3×
- —
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $35,113,000 | reported | |
| FY 2024 | 2024-12-31 | $2,557,000 | reported | |
| FY 2023 | 2023-12-31 | $0 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported | |
| FY 2021 | 2021-12-31 | $0 | reported | |
| FY 2020 | 2020-12-31 | $3,000,000 | reported | |
| FY 2019 | 2019-12-31 | $0 | reported | |
| FY 2018 | 2018-12-31 | $0 revised | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2023 | — | $0.00 | $0.00 | — | 167.94M sh | +37.4% | — |
| FY2022 | — | $0.00 | $0.00 | — | 122.21M sh | +296.7% | — |
| FY2021 | — | $2.00M | $2.00M | — | 30.81M sh | +77.2% | — |
| FY2020 | — | $0.00 | $0.00 | — | 17.38M sh | +7.7% | — |
| FY2019 | — | $0.00 | $0.00 | — | 16.13M sh | +10.2% | — |
Segments
LineFY2024ShareChange
UNITED STATES$3.20M412%−25.6%
AUSTRIA$1.70M219%−19.0%
Total$776.00K
Biological products, except diagnostic substances
X4 Pharmaceuticals, Inc is the 51st largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
FENCFennec Pharmaceuticals Inc.$44.6M6.1%21.8%$381.4MCHRSCoherus Oncology, Inc.$42.2M59.8%398.4%$83.4MEDITEditas Medicine, Inc.$40.5M25.4%395.0%$329.5MVYGRVoyager Therapeutics, Inc.$40.4M49.5%296.5%$105.8MSGMOQSangamo Therapeutics, Inc$39.6M31.6%310.8%$58.0MKYMRKymera Therapeutics, Inc.$39.2M16.7%794.0%$10.9BCCCCC4 Therapeutics, Inc.$35.9M1.0%292.1%$405.1M
XFORX4 Pharmaceuticals, Inc (this company)$35.1M1,273.2%225.6%$324.2M
SCLXScilex Holding Co$30.3M46.5%1,236.4%$13.2MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
X4 Pharmaceuticals, Inc · CIK 1501697 · Engraved from SEC EDGAR